Seattle Genetics (SGEN) Misses Q2 EPS by 12c, Offers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Cowen Raises Price Target on Seattle Genetics (SGEN) Following 2Q15
July 31, 2015 8:46 AM EDTCowen reiterated a Market Perform rating on Seattle Genetics (NASDAQ: SGEN), and raises the price target to $40.50 (from $34.00), following 2Q15 results. SGEN posted Adcetris sales of $55.1M for 2Q15, ahead of consensus $50.9M estimates.
Analyst Boris Peaker commented, "SGEN reported 2Q15... More
